SCHEMBL205919

SCHEMBL205919

CN(C)C1(Cc2cccc(Cl)c2)CCC(NC(=O)CCC(=O)N2CCN(c3ccccc3F)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 2/20 0.51
KMT2A Q03164 5/20 0.46
NPC1 O15118 1/20 0.44
MAPT P10636 4/20 0.44
MEN1 O00255 4/20 0.44
TSHR P16473 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.43
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SIGMAR1 Q99720 2/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205991 0.88 USP2 (0.52) MAPTLMNAHTTALDH1A1L3MBTL1
SCHEMBL4081400 0.87 SIGMAR1 (0.46) KMT2ANPC1MAPTMEN1TSHR
SCHEMBL205163 0.85 SIGMAR1 (0.44) KMT2ANPC1MEN1LMNAALDH1A1
SCHEMBL208174 0.84 SIGMAR1 (0.43) KMT2ANPC1MAPTMEN1ALDH1A1
SCHEMBL207761 0.84 ALDH1A1 (0.51) KMT2ANPC1MAPTMEN1LMNA
SCHEMBL207068 0.83 USP2 (0.50) MAPTLMNAHTTTP53POLB
SCHEMBL4081492 0.83 HTR1A (0.45) NPC1TSHRALDH1A1SIGMAR1
SCHEMBL4072326 0.81 SIGMAR1 (0.49) CACNA1GKMT2AMEN1LMNASIGMAR1
SCHEMBL207353 0.81 THRB (0.43) KMT2ANPC1MAPTMEN1ALDH1A1
SCHEMBL206991 0.81 EPHX2 (0.43) KMT2ANPC1MAPTTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD CACNA1G 3509/4885KMT2A 3604/4885NPC1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.